Omega-3 supplementation compared to the placebo had no significant effect on AIP (− 0.11 ± 0.20 vs. ![]() Sixty diabetic patients with NAFLD were randomly assigned into the omega-3 (2000 mg/d omega-3 capsule contained 360 mg/d eicosapentaenoic acid and 240 mg/d docosahexaenoic acid) and the placebo (liquid paraffin) groups using computer-generated random number table. From August 2016 to March 2017, the subjects referred to Faghihi hospital in Shiraz, Iran, were recruited. We conducted a double-blind, randomized controlled trial (RCT) for 12 weeks. We investigated the effect of omega-3 supplementation on accurate and available cardiometabolic indices including atherogenic index of plasma (AIP), Castelli risk index I, Castelli risk index II and atherogenic coefficient (AC) in diabetic patients with NAFLD. Cardiometabolic indices can predict and evaluate the cardiometabolic risk. ![]() Omega-3 supplementation has been proposed as a possible strategy for management of cardiometabolic risk. Patients with non-alcoholic fatty liver disease (NAFLD) as well as type 2 diabetes mellitus (T2DM) are at increased risk for cardiovascular diseases (CVD).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |